Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.

Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, Alexander C.

J Manag Care Pharm. 2007 Oct;13(8):652-63.

3.

Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.

García Ruiz FJ, Marín Ibáñez A, Pérez-Jiménez F, Pintó X, Nocea G, Ahumada C, Alemao E, Yin D; REALITY Study Group.

Pharmacoeconomics. 2004;22 Suppl 3:1-12.

PMID:
15669149
4.

Correlates of repeat lipid testing in patients with coronary heart disease.

Virani SS, Woodard LD, Wang D, Chitwood SS, Landrum CR, Urech TH, Pietz K, Chen GJ, Hertz B, Murawsky J, Ballantyne CM, Petersen LA.

JAMA Intern Med. 2013 Aug 12;173(15):1439-44. doi: 10.1001/jamainternmed.2013.8198.

PMID:
23817669
5.

Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study.

Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, Zhao L, Zhang Q, Yan P.

Curr Med Res Opin. 2008 Jul;24(7):1951-63. doi: 10.1185/03007990802138731 . Epub 2008 Jun 10.

PMID:
18547466
6.
7.

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.

Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K.

J Clin Lipidol. 2014 Jan-Feb;8(1):107-16. doi: 10.1016/j.jacl.2013.09.009. Epub 2013 Oct 1.

PMID:
24528691
8.

Risk of cardiovascular events in patients at optimal values for combined lipid parameters.

Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ.

Curr Med Res Opin. 2007 Mar;23(3):553-63.

PMID:
17357251
10.

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.

Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.

12.

Lipid management and cholesterol goal attainment in Norway.

Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgström F, Jönsson L.

Am J Cardiovasc Drugs. 2006;6(2):121-8.

PMID:
16555865
13.

The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.

Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D.

Am J Cardiovasc Drugs. 2006;6(6):383-91.

PMID:
17192128
14.
15.

Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.

Jones PH, Nair R, Thakker KM.

J Am Heart Assoc. 2012 Dec;1(6):e001800. doi: 10.1161/JAHA.112.001800. Epub 2012 Dec 19.

18.

Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.

Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ.

J Manag Care Pharm. 2010 May;16(4):264-75.

19.

The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study.

Diamantopoulos EJ, Athyros VG, Yfanti GK, Migdalis EN, Elisaf M, Vardas PE, Manolis AS, Karamitsos DT, Ganotakis ES, Hatseras D; OLYMPIC Study Group.

Angiology. 2005 Nov-Dec;56(6):731-41.

PMID:
16327950
20.

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus.

Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ.

Cardiovasc Diabetol. 2012 Sep 14;11:109. doi: 10.1186/1475-2840-11-109.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk